Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03552393 · ClinicalTrials.gov registry record · Phase 2

Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.

A Phase 2 study of Anemia and Renal Insufficiency, Chronic, sponsored by Hoffmann-La Roche.

Completed
Registry status
Phase 2
Development phase
40
Enrollment target
20
Study locations

NCT03552393 is a Phase 2 study of Anemia and Renal Insufficiency, Chronic that has completed, run by Hoffmann-La Roche. The registered enrollment target is 40 participants, below the 427-participant average among 72 other Anemia trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03552393, a Phase 2 study of Anemia and Renal Insufficiency, Chronic, has completed, sponsored by Hoffmann-La Roche.

COMPLETED
Registry status
Phase 2
Development phase
40 participants
Enrollment target
20
Study locations

Study Summary

Ascertain the starting dose of Mircera given subcutaneously for the maintenance treatment of anemia in pediatric participants with chronic kidney disease (CKD) on dialysis or not yet on dialysis when switching from stable subcutaneous (SC) maintenance treatment with epoetin alfa, epoetin beta, or darbepoetin alfa.

Conditions Studied

Anemia Renal Insufficiency, Chronic

Interventions

  • DRUG Mircera

Study Locations (20)

Other

  • Hopital Jeanne De Flandre; Pediatrie - Lille
  • Gh Necker Enfants Malades; Nephrologie - Paris
  • Höpital Hautepierre; Pediatrie 1 - Strasbourg
  • Semmelweis University; 1st Department of Pediatrics, Pediatric Nephrology Center - Budapest
  • Debreceni Egyetem Klinikai Központ; Gyermekklinika - Debrecen
  • Vilnius University Children's Hospital - Vilnius
  • Uniwersyteckie Centrum Kliniczne; Klinika Chorob Nerek i Nadciśnienia Dzieci i Mlodziezy - Gdansk
  • Uniwersytecki Szpital Dziecięcy w Krakowie; Oddz.Nefrologii i Nadciśnienia Tętniczego/Stacja Dializ - Krakow
  • Instytut "Centrum Zdrowia Matki Polki; Klinika Pediatrii i Immunologii i Nefrologii - Lodz
  • Szpital Specjalistyczny dla Dzieci i Doroslych; Oddzial Kliniczny Pediatrii i Nefrologii - Torun
  • Szpital Kliniczny nr 1 im. prof. Szyszko; Oddz. Nefrologii Dzieciecej z Pododdziałem Dializoterapii - Zabrze

Alabama

  • University of Alabama at Birmingham; Pediatric Nephrology - Birmingham

California

  • Loma Linda University health - Loma Linda

Georgia

  • Emory University School of Med; Pediatrics - Atlanta

Missouri

  • Children'S Mercy Hospital; Pediatric Nephrology - Kansas City

New Jersey

  • RWJBarnabas Health - West Orange

North Carolina

  • East Carolina University; Brody School of Medicine - Greenville

Texas

  • UT Southwestern Medical Center; Pediatrics Dept. - Dallas

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2018-08-03
Est. Completion 2021-07-19
Phase Phase 2

Sponsor

Hoffmann-La Roche

909 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03552393

The ClinicalTrials.gov registry entry for NCT03552393 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 427-participant average among 72 other Anemia trials with a reported enrollment target (91% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Anemia appearing as the primary indexed condition, and to 1 intervention - of which Mircera is the first listed.

NCT03552393 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, Alabama, California.

Frequently Asked Questions

What is clinical trial NCT03552393 about?

NCT03552393 is a clinical study titled "Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.". Ascertain the starting dose of Mircera given subcutaneously for the maintenance treatment of anemia in pediatric participants with chronic kidney disease (CKD) on dialysis or not yet on dialysis when switching from stable subcutaneous (SC) maintenance treatment with epoetin alfa, epoetin beta, or da...

What is the current status of trial NCT03552393?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2018-08-03. Estimated completion is 2021-07-19.

What conditions does trial NCT03552393 study?

This clinical trial studies the following conditions: Anemia, Renal Insufficiency, Chronic.

What interventions are being tested in trial NCT03552393?

The interventions under investigation include: Mircera (DRUG).

Who is sponsoring clinical trial NCT03552393?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03552393 being conducted?

This trial has 20 study locations across Alabama, California, Georgia, Missouri, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Anemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Anemia

All registered trials for this condition

Renal Insufficiency, Chronic

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.